The strategic committee of Op2lysis is composed of 6 members with complementary skills and experience. All are experts in their field. The committee is in charge of endorsing the corporate strategy. It is also in charge of following the implementation of the corporate project. The strength of this strategic committee relies in the complementarity of members’ experience, as well as in a strong commitment to Op2lysis.
Co-founder of Op2lysis, Jérôme has extensive experience in neurovascular research and stroke.
With a training in Agronomy Engineering and a PhD in Neurosciences, Jérôme completed his scientific background with a training in entrepreneurship at HEC, Paris (Challenge + program).
Over the past ten years, Jérôme has worked in the Inserm Unit (U1237), led by Professor Denis Vivien in Caen, to develop innovative therapeutic solutions to destroy blood clots. He is the co-inventor of Opt-PA, the formulated O2L-001 molecule.
Jérôme is in charge of the company’s operational and research activities.
Doctor specialist and co-founder of the company, Christophe has been in charge of cardiovascular and thrombosis development at Sanofi for the past 20 years.
With a MD degree, he has successfully developed and registered internationally many cardiovascular drugs, including antithrombotic products now widely used in coronary artery diseases, such as myocardial infarction.
Christophe is in charge of the management of the company, and foresees development activities.
Thierry Sempere is the President of WICAP Op2lysis, the holding company representing the shareholders who invested in the first Op2lysis fundraising following a crowdfunding campaign with Wiseed.
Thierry’s professional career in the pharmaceutical industry, including high-level international operational experience, is a real contribution for the company.